GENE ONLINE|News &
Opinion
Blog

2021-09-11| Asia-Pacific

Korea’s First Private-Led New Drug Cluster to Launch in Late September

by Tyler Chen
Share To
Photo: Woojung Bio

South Korea’s CRO firm Woojung Bio planned on launching the first private-led new drug cluster in Korea at the end of September. The goal is to elevate Korean biotech’s ability to develop innovative drugs in the highly competitive market.

Provide R&D Infrastructures and Clinical Consulting Services

 

As the building will finish construction in late September, the cluster is expected to provide R&D infrastructures, analysis centers, and consulting services from nonclinical trials to clinical trials. Woojung Bio said the private-led cluster is able to work closely with the biotechs and move faster and more flexibly than the government-led cluster.

Partnering Up with Former Deputy Director of the USFDA

 

Since 2018, Woojung Bio has signed MOUs with 28 companies and institutions for the cluster. A few days ago, the firm penned an MOU with Ahn Bio Consulting, a powerhouse in clinical trials consultation for all stages of drug development and licensing. Its founder Hae Young Ahn is a former and the first Korean deputy director of the USFDA.

Ahn Bio Consulting is able to provide critical regulatory strategies in new medicine, the collaboration will also discover and cultivate domestic bio startups.

Other MOUs Signed

 

In late August, Woojung Bio struck a deal with Medirama to establish a bio cooperative system. Other than providing clinical consultation, the two firms will work together to eliminate drug candidates that failed to meet the criteria and help biotechs to expand their business to overseas countries.

Moreover, the collaboration will build an animal center and research center in the about-to-established cluster.

Woojung Bio also approached venture capitals, including Daily Partners, Spring Camp, Samho Green Investment, and bio associations such as Korea Biotechnology Association and Korea New Drug Development Research Association to form a more wholesome ecosystem in the cluster.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
R&D
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
AstraZeneca’s severe asthma drug Tezspire has been granted market authorization in South Korea
2023-12-25
LATEST
Profluent Achieves Human Genome Editing Milestone Using OpenCRISPR-1: The First AI-Generated, Open-Source Gene Editor
2024-05-08
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
EVENT
Scroll to Top